Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025142 · ClinicalTrials.gov registry record · Phase 2
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00025142: Completed Phase 2 study, sponsored by Stanford University.
NCT00025142 is a Phase 2 study that has completed, run by Stanford University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025142, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with gefitinib may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gefitinib and oxaliplatin combined with leucovorin and fluorouracil in treating patients who have advanced solid tumors or colorectal cancer.
Interventions
- DRUG FOLFOX regimen
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
What the finished NCT00025142 record still lists
NCT00025142 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which FOLFOX regimen is the first listed.
NCT00025142 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00025142 about?
NCT00025142 is a clinical study titled "Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer". RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with gefitinib may kill more tumo...
What is the current status of trial NCT00025142?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-07. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00025142?
The interventions under investigation include: FOLFOX regimen (DRUG), oxaliplatin (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00025142?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia